TARIBAVIRIN HYDROCHLORIDE

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C8H13N5O4.ClH
Molecular Weight	279.681
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.NC(=N)C1=NN(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O

InChI

InChIKey=PIGYMBULXKLTCJ-UHSSARMYSA-N

InChI=1S/C8H13N5O4.ClH/c9-6(10)7-11-2-13(12-7)8-5(16)4(15)3(1-14)17-8;/h2-5,8,14-16H,1H2,(H3,9,10);1H/t3-,4-,5-,8-;/m1./s1

HIDE SMILES / InChI

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT00230958 | https://www.ncbi.nlm.nih.gov/pubmed/19040344 | https://ir.bauschhealth.com/news-releases/2010/01-11-2010

Taribavirin, an oral prodrug of ribavirin that was developed as nucleoside antimetabolite, which interferes with duplication of viral genetic material. Taribavirin was studied in phase III clinical trial for the treatment of chronic hepatitis C patients. However, this drug not yet approved for pharmaceutical use.

Originator

Approval Year

PubMed

Title	Date	PubMed
Hepatitis C treatment: current and future perspectives.	2010-11-01	21040548
The next step for taribavirin.	2010-10	20879028
Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.	2010-10	20721883
Antiviral therapy for hepatitis C virus: beyond the standard of care.	2010-04	21994657
New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents.	2010	21694902
Hepatitis C and kidney disease.	2010	21188196
A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results.	2009-09	19585653
Ribavirin analogs.	2009-08	19628158
Taribavirin for the treatment of chronic hepatitis C.	2008-12	19040344
Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study.	2007-07	17470380
Therapeutic issues in HIV/HCV-coinfected patients.	2007-06	17501757
In vitro and in vivo influenza virus-inhibitory effects of viramidine.	2005-10	16087250
Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin.	2004-10	15388466
A simple assay for determining antiviral activity against Crimean-Congo hemorrhagic fever virus.	2004-04	15026198
Viramidine (Ribapharm).	2002-11	12476957
Identification of active antiviral compounds against a New York isolate of West Nile virus.	2002-07	12076755
Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections.	1994-10	7847873
Treatment of lethal Pichinde virus infections in weanling LVG/Lak hamsters with ribavirin, ribamidine, selenazofurin, and ampligen.	1993-01	8384433
Effects of ribamidine, a 3-carboxamidine derivative of ribavirin, on experimentally induced Phlebovirus infections.	1988-12-01	2976263
Synthesis and antiviral activity of 1,2,4-triazole-3-thiocarboxamide and 1,2,4-triazole-3-carboxamidine ribonucleosides.	1973-08	4355593

Sample Use Guides

In Vivo Use Guide

viramidine (TARIBAVIRIN) 600 mg BID

Route of Administration: Oral

Name

Type

Language

TARIBAVIRIN HYDROCHLORIDE [MI]

Preferred Name

English

TARIBAVIRIN HYDROCHLORIDE

Official Name

English

TARIBAVIRIN HYDROCHLORIDE [USAN]

Common Name

English

VIRAMIDINE

Brand Name

English

1-.BETA.-D-RIBOFURANOSYL-1H-1,2,4-TRIAZOLE-3-CARBOXIMIDAMIDE MONOHYDROCHLORIDE

Common Name

English

TARIBAVIRIN HCL

Common Name

English

1H-1,2,4-TRIAZOLE-3-CARBOXIMIDAMIDE, 1-.BETA.-D-RIBOFURANOSYL-, MONOHYDROCHLORIDE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C281